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BH3 mimetics efficiently induce apoptosis in mouse
basophils and mast cells
Ramona Reinhart1, Lionel Rohner2, Simone Wicki1, Michaela Fux2 and Thomas Kaufmann*,1
Basophil granulocytes and mast cells are recognized for their roles in immunity and are central effectors of diverse immunological
disorders. Despite their similarities, there is emerging evidence for non-redundant roles of the circulating yet scarce basophils and
tissue-resident mast cells, respectively. Because of their importance in allergic pathogenesis, specific induction of apoptosis in
basophils and mast cells may represent an interesting novel treatment strategy. The pro-inflammatory cytokine interleukin-3
serves as a key factor for basophil and mouse mast cell survival. Interleukin-3 increases the expression of anti-apoptotic BCL-2
family members, such as BCL-2, BCL-XL or MCL-1; however, little is known how strongly these individual proteins contribute to
basophil survival. Here, we were applying small molecule inhibitors called BH3 mimetics, some of which show remarkable success
in cancer treatments, to neutralize the function of anti-apoptotic BCL-2 family members. We observed that expression levels of
anti-apoptotic BCL-2 proteins do not necessarily correlate with their respective importance for basophil survival. Whereas naive
in vitro-differentiated mouse basophils efficiently died upon BCL-2 or BCL-XL inhibition, interleukin-3 priming rendered the cells
highly resistant toward apoptosis, and this could only be overcome upon combined targeting of BCL-2 and BCL-XL. Of note,
human basophils differed from mouse basophils as they depended on BCL-2 and MCL-1, but not on BCL-XL, for their survival at
steady state. On the other hand, and in contrast to mouse basophils, MCL-1 proved critical in mediating survival of interleukin-3
stimulated mouse mast cells, whereas BCL-XL seemed dispensable. Taken together, our results indicate that by choosing the right
combination of BH3 mimetic compounds, basophils and mast cells can be efficiently killed, even after stimulation with potent pro-
survival cytokines such as interleukin-3. Because of the tolerable side effects of BH3 mimetics, targeting basophils or mast cells
for apoptosis opens interesting possibilities for novel treatment approaches.
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Together with neutrophils and eosinophils, basophils belong to
the granulocyte fraction of circulating blood leukocytes that are
recruited to sites of infection.1 Even though basophils
constitute o1% of circulating leukocytes, they were recog-
nized for their pivotal functions in immunity. Besides their
essential effector function during helminth infections,2,3
basophils have a prominent role in the acquired, antibody-
mediated immunity against ticks.4 Importantly, basophils also
contribute to a variety of immunological disorders, including
non-redundant key roles in immunoglobulin G (IgG)-mediated,
but not IgE-mediated, systemic anaphylaxis in mice5 and
critical regulatory and effector functions in immediate, late-
phase and a form of delayed hypersensitivity reaction
described as cutaneous basophil hypersensitivity.6–9
Basophils share several key features with mast cells, even
though the latter are tissue-resident. Basophils and mast cells
are closely related in the mouse as they develop from a
common precursor10 and, importantly, both cell types express
the high-affinity receptor for IgE, FcεRI, on their surfaces.
Moreover, both cell types contain granules of similar content,
including TH2-associated cytokines such as IL-4 and IL-13,
preformed mediators, like proteases, proteoglycans and
histamine, as well as de novo synthesized lipid mediators.11
Despite these similar features and certain overlapping
functions, there is increasing evidence that basophils and
mast cells do also exert important non-redundant roles
(reviewed in Karasuyama et al.12 and Galli13). Of note, mouse
basophils differ in several aspects from human basophils, but
still functionally correspond to each other.14
Numerous previous studies have demonstrated that IL-3 is
a critical cytokine for basophil and mast cell differentiation and
survival.15,16 However, in contrast to basophils, IL-3 drives
ex vivo differentiation of mouse, but not human, mast cells.17
As seen in human basophils, IL-3 upregulates the protein
expression of anti-apoptotic MCL-1, BCL-XL, BCL-2 and
cIAP2,18,19 and protects basophils not only from intrinsic
apoptotic stresses18 but also from TRAIL-, IFNα- or
FasL-mediated apoptosis.19 However, even though several
anti-apoptotic BCL-2 family members were shown to be
upregulated in basophils upon IL-3 stimulation, their distinct
and specific functional impact on basophil viability remains to
be investigated. To address the question of how importantly
individual pro-survival proteins contribute to basophil survival
and whether this regulation is distinct from mast cell survival,
we took advantage of a newly developed class of small
molecule compounds, called BH3mimetics. BH3mimetics act
as inhibitors of anti-apoptotic BCL-2 family members by
interfering with protein–protein interactions. Because of the
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improvement of their chemical structure and properties, BH3
mimetics are now available to specifically target individual
family members, including BCL-2,20 BCL-XL
21,22 and
MCL-1.23–25 The BCL-2 selective drug ABT-199 (Venetoclax)
has recently been approved for the use in aggressive forms of
chronic lymphocytic leukemia (CLL) due to its high efficacy
and tolerable side effects.26 Even though BH3 mimetics were
developed as anti-cancer therapeutics, it is conceivable to
speculate that they may be useful to eliminate activated
immune cells implicated with certain immunological disorders.
In this study, functional testing of BH3 mimetics could not only
reveal the importance of the distinct anti-apoptotic BCL-2
family members for basophil and mast cell survival, but also
indicate that anti-apoptotic BCL-2 proteins may represent
molecular targets in activated basophils or mast cells to
overcome IL-3-induced survival enhancement, for example, in
allergic disorders.
Results
IL-3 induces anti-apoptotic BCL-2 family members, while
BH3 mimetics promote caspase-3 processing in mouse
basophils. We performed qPCR array analysis in
IL-3condHoxb8 basophils originating from conditionally immor-
talized mouse bone marrow progenitors27,28 (further referred
to as in vitro-differentiated mouse basophils) to study the
impact of IL-3 on genes regulating apoptosis. As shown in
Figure 1, IL-3 increased pro-survival genes such as Bcl-2,
Bcl-xL and Mcl-1 in mouse basophils, while pro-apoptotic
genes like caspase-2, -3, -9 and Bim were downregulated
(see Supplementary Table S1 for full array list). We focused
on pro-survival members of the BCL-2 family, as they likely
account for the IL-3-mediated pro-survival effects. We first
validated the IL-3-induced increase in mRNA levels of Bcl-2,
Mcl-1 and Bcl-xL by qPCR using independent primer sets
(Figure 2a). Moreover, IL-3 reduced the transcription of the
pro-apoptotic BH3 only gene Puma, while Bim levels
remained unaffected (Figure 2a). Similar to human
basophils,18 in vitro-differentiated mouse basophils
expressed readily detectable protein levels of MCL-1,
BCL-2 and BCL-XL at steady state, which further increased
upon administration of a high concentration of IL-3 (10 ng/ml),
whereas the amount of processed caspase-3 (formation of
the active p17 large subunit) strongly decreased in the
presence of IL-3 (Figures 2b and c, and Supplementary
Figure S1). These results largely concur with IL-3-mediated
pro-survival effects reported in human primary basophils,18,19
supporting that the IL-3-driven signaling pathways in in vitro-
differentiated mouse basophils are comparable to human
basophils.
Taking advantage of BH3 mimetic compounds, which inhibit
the pro-survival activities of MCL-1 (A-121047729), BCL-2
(ABT-199/Venetoclax20), BCL-XL (WEHI-539
22), or both
BCL-2 and BCL-XL (ABT-263/Navitoclax
21), we investigated
the importance of those distinct pro-survival proteins for
mouse basophil viability. As shown in Figures 2b and d,
treatment with the individual BH3mimetics all strongly induced
the formation of the active caspase-3 p17 large subunit, which
was reduced upon co-administration of IL-3. This decrease in
caspase-3 processing was partially overcome by blocking of
BCL-XL, whereas single antagonism of BCL-2 or MCL-1 only
had minor effects (Figures 2b and d). Importantly, however,
Figure 1 IL-3 induces pro-survival BCL-2 family genes, while pro-apoptotic genes are decreased in mouse basophils. PCR array for genes regulated in apoptotic pathways.
In vitro-differentiated mouse basophils were kept either under cytokine-omitted or IL-3 (10 ng/ml)-exposed conditions for 2 h. Using the SA Biosciences software, Ct values were
normalized to the average of five different housekeeping genes (β actin, β2 microglobulin, Gapdh, Gusb and Hsp90ab1) and linearized with the standard formula for qPCR
(2 − (Ctsample−Ctcontrol)). While the y axis displays the expression of IL-3-treated cells, the x axis shows corresponding levels of untreated cells. Continuous line matches the
expression upon IL-3 with the expression of untreated, while dotted lines display a threshold of twofold increase/decrease of the mRNA expression comparing IL-3 over untreated.
See complete gene list in Supplementary Table S1
Impact of BH3 mimetics on basophils and mast cells
R Reinhart et al
2
Cell Death and Differentiation
Figure 2 Regulation of pro- and anti-apoptotic proteins by IL-3, and effects of BH3 mimetics, in mouse basophils. (a) qPCR analysis depicting fold change of the mRNA
expression in in vitro-differentiated basophils upon IL-3 treatment compared to untreated after 2 h of incubation; data represent means±S.D., n= 6. Statistical analysis by
unpaired t-test with post hoc Holm–Sidak multiple comparison correction. (b) Protein levels of in vitro-differentiated basophils after 4 h of incubation with different BH3 mimetics at
indicated concentrations with or without IL-3 (10 ng/ml), shown by a representative quantitative western blot using near-infrared fluorescence (n⩾ 3). (c) Quantitative analysis of
western blot as shown in (b) normalized to tubulin, displaying fold change of the protein level of BCL-2, BCL-XL, MCL-1, BIM and processed caspase-3 (p17 active large subunit)
upon IL-3 over untreated; data represent means±S.D., n= 5. (d) Quantified protein levels of active caspase-3 p17 large subunit as fold change relative to tubulin expression
upon BH3 mimetics treatment alone (white bar) or combined with 10 ng/ml IL-3 stimulation (gray bar); n⩾ 2, means± S.D.
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combined targeting of BCL-2 and BCL-XL (ABT-263) or BCL-2
and MCL-1 (ABT-199+A-1210477) could fully overcome IL-3-
mediated protection, inducing strong caspase-3 processing
already as early as 4 h after stimulation (Figures 2b and d).
Those results suggest that the simultaneous inhibition of
BCL-2 and BCL-XL can effectively induce activation of
apoptotic effector caspases and that this may overcome
IL-3-mediated mouse basophil survival.
The combined inhibition of BCL-2 and BCL-XL fully
neutralizes IL-3-mediated pro-survival effects in mouse
basophils over time. Using a caspase-3 activity assay, we
formally proved that the observed increase of the caspase-3
p17 subunit on immunoblots correlates with increased
enzymatic activity (Figure 3a). Quantification of these data
by flow cytometry further underlined that ABT-263 could
significantly increase caspase-3 activity and loss of cell
membrane integrity compared to the other BH3 mimetics,
both in the absence or presence of IL-3 (Figure 3b, and
corresponding statistics in Supplementary Table S2).
Quantification of cellular viabilities (GFP-Annexin V/PI
exclusion) over time showed that the spontaneous cell death
of in vitro-differentiated mouse basophils was strongly delayed
upon addition of high IL-3 concentrations and fully blocked by
the pan-caspase inhibitor Q-VD-Oph, indicating that the cells
died by classical apoptosis (Figure 3c, and Supplementary
Figure S2). We next treated mouse basophils with BH3
mimetics to evaluate their long-term effects on survival. As
shown in Figure 3c, single targeting of BCL-2 or BCL-XL
further reduced the viability of basophils in the absence of
cytokine, with nearly all cells being dead after 24 h (Po0.0001
at 24 h for both ABT-199 and ABT-263, two-way ANOVA and
Sidak’s correction, compared to untreated), while targeting of
MCL-1 had only a minor effect over untreated control
(P= 0.0078 at 24 h, all other time points NS, two-way ANOVA
and Sidak’s correction). Interestingly, whereas single inhibition
of BCL-2 or BCL-XL could partially counteract the IL-3-induced
pro-survival effects (P-values for 24 h/48 h/72 h/96 h: ABT-199,
NS/0.0021/o0.0001/o0.0001; WEHI-539, 0.0044/0.0002/
o0.0001/o0.0001, two-way ANOVA and post hoc Sidak’s
correction for multiple comparison, compared to IL-3 alone),
blocking MCL-1 with A-1210477 had no such effect
(Figure 3c). Of note, when BCL-2 and BCL-XL were
simultaneously blocked by ABT-263, the IL-3-mediated
survival benefit was completely abolished (Figure 3c, P-value
o0.0001 for all time points, two-way ANOVA and post hoc
Sidak’s correction for multiple comparison over IL-3 alone). In
summary, these data suggest that, over time, the individual
targeting of BCL-2 and BCL-XL is only partially able to
overcome IL-3-mediated basophil survival, while the com-
bined targeting fully abrogates it. Furthermore, even though
MCL-1 is upregulated by IL-3, inhibition of MCL-1 alone is
insufficient to counteract the IL-3-mediated pro-survival
effects.
BCL-2 and MCL-1 are required to maintain viability of
human primary basophils. Similar to mouse basophils, we
identified BCL-2 as a critical protein maintaining the steady
state survival of human basophils, whereas – in contrast to
mouse basophils – we found that blocking MCL-1 significantly
decreased human basophil viability, while blocking of BCL-XL
had no such effect (Figure 4a and Supplementary Figure S3).
Cell death could be blocked by the pan-caspase inhibitor
Q-VD-Oph, demonstrating that classical apoptosis was the
underlying mechanism (Figure 4a). Treating human primary
basophils with the different BH3 mimetics decreased BCL-2
and MCL-1 protein levels, correlating with an increase in
caspase-3 activity (Figures 4b and c, and statistics in
Supplementary Table S3). Taken together, we could reveal
that BCL-2 and MCL-1 have an independent key role in
maintaining the viability of human primary basophils, while, in
contrast to mouse basophils, BCL-XL seems to be
dispensable.
BCL-2 and MCL-1 are important in maintaining mouse
mast cell viability. To investigate whether anti-apoptotic
BCL-2 family members regulate basophil or mast cell survival
differently, we next investigated the effects of IL-3 and the
killing potential of BH3 mimetics on mouse mast cells, using
the well-accepted in vitro-differentiation protocol from bone
marrow.30 Bone marrow-derived mast cells (BMMC) were
differentiated in IL-3 enriched medium for at least 4 weeks,
resulting in a c-kit+FcεRI+ population of high purity
(Supplementary Figure S4).
qPCR array analysis showed that IL-3 increases pro-
survival genes such as Bcl-2 and Bcl-xL, while pro-apoptotic
genes like caspase-3, Bad and Bim were downregulated
(Figure 5a, and Supplementary Table S1 for full array list).
Validation with independent primer sets confirmed that, similar
to mouse basophils, IL-3 transcriptionally induced the mRNA
expression of Bcl-2, Bcl-xL (P-values 0.0036/0.0054) andMcl-
1 (NS), while Puma was downregulated (Figure 5b). Addition
of high concentration of IL-3 increased MCL-1 protein levels,
but less so BCL-2 and BCL-XL levels (Figures 5c and d),
decreased caspase-3 activity, spontaneous mast cell apopto-
sis and significantly counteracted BH3 mimetics-induced
apoptosis (Figures 6a–c). The most pronounced induction of
BMMC cell death at early time points could be seen upon the
inhibition of either MCL-1, BCL-2 or the combined inhibition of
BCL-XL with BCL-2. However, only the latter could significantly
overcome the IL-3-induced pro-survival effect already after 6 h
(Figure 6b, two-way ANOVA, Turkey’s multiple comparisons
test, P-value=0.0007).
Figure 3 Viability of mouse basophils highly depends on BCL-2 and BCL-XL while MCL-1 is dispensable. (a) Detection of enzymatically active caspase-3 (green) and loss of
plasma membrane integrity (PI staining, orange) in in vitro-differentiated basophils after 6 h of treatment with indicated BH3 mimetics, with and without IL-3, measured by
CellEvent assay and subsequent analysis by fluorescence microscopy. One randomly selected picture from at least two independent experiments is shown. (b) Quantitative
analysis of caspase-3 activity and PI positivity by flow cytometric measurement of the same samples visualized in (a) (see statistical analysis in Supplementary Table S2). (c)
Kinetic viability measurement (GFP-Annexin V/PI exclusion) of in vitro-differentiated basophils in IL-3-free or IL-3 enriched medium treated with various BH3 mimetics at indicated
concentrations and time points by flow cytometry; n⩾ 5, (except n⩾ 3 for WEHI-539), data represent means±S.D.
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At later time points, a critical role for BCL-2 in maintaining
BMMC viability could be confirmed, as single treatment with
ABT-199 markedly reduced viability in the absence of IL-3 and
partially, but significantly, counteracted the pro-survival effects
of IL-3 (Figure 6c, two-way ANOVA, Sidak’s multiple compar-
isons test; P-value o0.0001 for all time points). Not surpris-
ingly, similar results were obtained with ABT-263 single
treatments (P-value o0.0001 for all time points). In contrast,
however, BCL-XL inhibition only showed minor effects on
BMMC viability, indicating that – especially in the presence of
IL-3 – the anti-apoptotic function of BCL-XL is either less
important in BMMCs or might be compensated by other family
members. Moreover, and in contrast to mouse basophils, we
revealed an important role of MCL-1 for the survival of mouse
BMMC (Figure 6c, P-value o0.0001 for all time points with
10 μMA-1210477 in the presence of IL-3 and for 24 h and 48 h
time points in the absence of IL-3). These results show that
BCL-2 as well as MCL-1 have pivotal roles in cell death
regulation of BMMC.
Discussion
The pro-inflammatory cytokine IL-3 is known to inhibit
apoptosis in many cells, including basophils18 and mouse
mast cells,31 both of which are important effector cells in
allergic diseases in which IL-3 is released from allergic
tissue.32 Importantly, non-redundant roles of basophils in
allergic inflammation are emerging, which in turn may also
involve chronicity.33 To enable new treatment possibilities in
diseases correlating with basophil or mast cell hyperreactivity,
a better understanding of their distinct cell survival regulation
is needed.
With this study, we could reinforce that, besides its role in
basophil and mouse mast cell development and differentia-
tion, IL-3 has an important role in enhancing basophil and
mast cell survival.15,32,34–36 Interestingly, even though the
receptors for IL-5 andGM-CSF share the common β chain with
the IL-3 receptor, IL-3 seemsmost potent in enhancing cellular
viability and inducing pro-survival BCL-2 family members in
basophils and mast cells.18,19,32 However, whether and how
this increase in specific anti-apoptotic proteins correlates with
prolonged basophil and mast cell viability is not fully under-
stood. We recognized that assessing mRNA or protein levels
of the distinct BCL-2 family members alone is insufficient to
predict relevance without functional readouts, which we
performed upon treatment with BH3 mimetic compounds.
Primarily, we could see that IL-3 rapidly induces the
transcription of pro-survival BCL-2 family members (e.g.,
Bcl-2,Mcl-1, Bcl-xL) in mouse basophils and mast cells, which
execute important pro-survival functions. We found that IL-3
induces subtly different expression patterns of BCL-2 family
genes in basophils compared to mast cells. While Bcl-xL was
the most strongly induced member in mouse basophils, Bcl-2
induction was more prominent in mast cells. This might
indicate that the survival regulation by BCL-2 family members
differs in the two cell types. Pro-apoptotic genes (e.g., Puma,
caspases) were downregulated in both cell types, further
enhancing survival. In mast cells, PUMA has previously been
identified as a critical inducer of apoptosis in response to
cytokine withdrawal.37 Of note, protein levels of the BCL-2
family members altered by IL-3 did not necessarily correlate
with mRNA levels, pointing toward regulation of protein
stability at the post-translational level. This is well exemplified
in the case of MCL-1, which has a short half-life due to fast
proteasomal turnover.38 Moreover, as already reported in
previous studies, BCL-2 aswell as MCL-1 might be cleaved by
activated caspases.19,39
Interestingly, while Bim mRNA levels slightly decreased in
IL-3-treated mouse basophils, protein levels increased,
indicating post-translational stabilization of BIM
(Supplementary Figure S1). In analogy to GM-CSF-treated
neutrophils,40 increased BIM may serve to limit cytokine-
induced survival.
Our study is based on the effects of small molecule BH3
mimetic compounds, which were developed as anti-cancer
therapeutics. ABT-199/ Venetoclax was recently approved by
the FDA for aggressive forms of chronic lymphocytic leukemia
(CLL)26 and numerous clinical trials are ongoing in other
cancer entities or using other BH3 mimetics (reviewed in
Opydo-Chanek et al.41). As BH3 mimetics show high binding
specificities for their pro-survival BCL-2 protein(s), thereby
limiting possible side effects, it is conceivable to speculate that
those drugs may also be useful in other disease areas. Here,
we investigated the functional importance of BCL-2, BCL-XL
and MCL-1 in basophil and mast cell survival, and further
explored how potently single or combinational inhibition of
those proteins could overcome the pro-survival effects of IL-3.
The application of BH3 mimetic compounds benefits from its
acute inhibitory effect, thereby avoiding any potential selection
or compensatory processes, which might occur upon genetic
approaches.42 Therefore, our approach reflects the immediate
influence of specific loss-of-function of pro-survival proteins on
the fate decision of mature basophils andmast cells. It remains
possible that our described effects in vitro may not fully reflect
the in vivo situation.36 However, confirmation in vivo is
challenging, in particular in the mouse, due to the tissue
residency of mast cells and low frequency of basophils.
Using in vitro-differentiated mouse basophils,27,28 we
revealed that BCL-2 and BCL-XL prevent apoptotic cell death
at steady state and identified both BCL-2 and BCL-XL as
potential targets to counteract the IL-3-mediated pro-survival
effects. Especially the combined inhibition of both proteins by
Figure 4 Human primary basophils critically depend on BCL-2 and MCL-1 for their survival. (a) Flow cytometric analysis of human basophil viability (GFP-Annexin V/PI
exclusion) over time upon treatment with BH3 mimetics at indicated concentrations. Induced cell death was blocked by co-incubation with the pan-caspase inhibitor Q-VD-Oph
(100 μM); n⩾ 4, means±S.D. (b) Intracellular staining (IC) of BCL-2 (clone 100), MCL-1 (clone Y37) and active caspase-3 (clone D3E9) protein levels in human basophils
treated for 4 h with different BH3 mimetic compounds (1 μM ABT-199, 1 μM ABT-263, 1 μM WEHI-539, 10 μM A-1210477 or combinational treatments) measured by flow
cytometry; representative histograms of fluorescence intensity shown (n= 4). Quantitative evaluation of IC staining of BCL-2, MCL-1 and active caspase-3 protein levels as fold
change upon BH3 mimetic treatment over untreated; n= 4, means± S.D. (c) Quantitative analysis of CellEvent assay measuring protease activity of caspase-3 and PI positivity
by flow cytometry after 24 h of incubation using the same concentrations of BH3 mimetics as in (b); n= 4, means± S.D.; see Supplementary Table S3 for statistical analysis
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ABT-263 was able to fully neutralize the IL-3 induced survival
advantage. Contrarily, and even though MCL-1 also increased
upon IL-3 exposure, its functional importance for mouse
basophil survival is questioned. Blocking of MCL-1 function by
A-1210477 had no significant impact on mouse basophil
viability over time andwas insufficient to overcome the survival
effects of IL-3. Those results suggest that on one hand MCL-1
might have only a minor role in the cell survival regulation and/
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or may be compensated by other pro-survival proteins.
Alternatively, MCL-1 might be more important for non-cell
death-related functions, such as a previously reported role in
the maintenance of mitochondrial integrity and respiration.43
Whereas Lilla et al.44 have shown that MCL-1 expression is
critical for basophil and mast cell development in the mouse,
our data suggest that this family member is no longer essential
for survival of end-differentiated mouse basophils. On the
other hand, we found evidence that BCL-2 and MCL-1 have a
critical role in maintaining the integrity of human basophils,
while the single inhibition of BCL-XL by WEHI-539 fails to
induce significant cell death (Figure 4). Especially the
simultaneous administration of A-1210477 with as little as
0.1 μM ABT-199 lead to complete human basophil cell death,
demonstrating the critical importance of BCL-2 and MCL-1
(Supplementary Figure S3). This suggests that BCL-XL is
dispensable for human basophil survival regulation and points
toward subtle differences in cell death regulation between
mouse and human basophils, which may have important
implications with regards to therapeutic applicability, in
particular as BCL-XL inhibition in vivo is accompanied by
thrombocytopenia.
Mast cells develop from a common myeloid progenitor as
basophils in the mouse (reviewed in Sasaki et al.45). Despite
sharing several key features, mast cells and basophils also
fulfill distinct immunologic functions. Throughout our study, we
were using the well-established model of bone marrow-
derived c-kit(CD117)+FcεRI+ mast cells, BMMC (adapted from
Kalesnikoff and Galli30 and Jensen et al.46). BMMC do not
represent all the different tissue-resident mast cell populations
in vivo, but serve as a powerful model to study mast cell
function in vitro as well as in vivo.30 However, not only bone
marrow-derived precursor cells are able to mature into granule
filled c-kit(CD117)+FcεRI+ mast cells, but also spleen-derived
progenitors are capable to differentiate into mast cells with
comparable results as in BMMC upon BH3 mimetic treatment
(Supplementary Figure S4). This suggests that spleen-
derived mast cells are a suitable alternative or additive source
of in vitro-differentiated mouse mast cells.
Former studies showed that BIM- or PUMA-deficient mast
cells are partially resistant to cytokine withdrawal induced cell
death in vitro, whereas loss of both PUMA and BIM strongly
protect mast cells from apoptosis, to a similar extent seen
upon overexpression of BCL-2.37,47,48 Our results with
ABT-199 confirm the importance of BCL-2 in maintaining
mast cell viability and also support previous work that
demonstrated the efficacy of ABT-737 (an earlier, ABT-263
related BH3 mimetic) in killing mouse and human mast cells
both in vitro and in vivo.49 Furthermore, ABT-199 could
partially counteract the potent pro-survival signaling mediated
by IL-3. Interestingly, and in contrast to mouse basophils, we
found that MCL-1 contributes to BMMC survival and that the
IL-3-induced increase in MCL-1 was further contributing to
cytokine driven BMMC survival. Similarly, the combined
inhibition of BCL-2 and BCL-XL promoted significant apoptosis
of BMMC counteracting IL-3-mediated effects. Yet, the
inhibition of BCL-2 alone seemed to be sufficient to kill BMMC,
suggesting major importance of BCL-2 over BCL-XL. This
finding was further supported by the lack of cell death
induction by the BCL-XL selective drug WEHI-539. To further
substantiate our finding that BCL-2 and MCL-1 are critically
important pro-survival family members for BMMC survival, we
could demonstrate that already as little as 0.1 μM of ABT-199
leads to a potentiation of the single MCL-1 inhibition
(Supplementary Figure S5a).
Whether BH3mimetic compoundsmight find their way into a
clinical application for basophil and mast cell-driven diseases
requires further investigation and needs to be carried on to
in vivo models of allergic diseases. In particular, the route of
administration (e.g., local versus systemic) and possible side
effects caused by loss of other cell types need to be taken into
consideration.24 Also, the importance of non-apoptotic func-
tions of BCL-2 family members affected by BH3 mimetics
needs to be further assessed, as BCL-2 family members were
recognized to be also involved in the regulation of Ca2+
homeostasis, autophagy, non-apoptotic cell death pathways
as well as the cell cycle (summarized in Opydo-Chanek
et al.41). In particular, those ‘off-target’ functions are crucial
factors in potential clinical studies deciding on the degree of
beneficial outcome and severity of adverse effect on cells and
tissues involved in, or independent of, the region of immune
reaction.
In summary, we show that there is a notable potential of BH3
mimetic compounds to kill mouse basophils and mast cells,
both in their naive states as well as upon stimulation with a
pathophysiologically highly relevant pro-inflammatory cyto-
kine, IL-3, which renders the cells increasingly resistant
toward intrinsic apoptosis. We further provide evidence that
there are subtle but important differences in how mouse and
human basophils, as well as mouse basophils and mast cells,
respond to various BH3 mimetics, respectively. As a conse-
quence, by targeting the right combination of anti-apoptotic
BCL-2 family members, it may be possible to selectively
eliminate activated basophils or mast cells, respectively,
opening interesting possibilities for potential therapeutic
Figure 5 IL-3-induced transcriptional upregulation of pro-survival BCL-2 family members in mouse mast cells. (a) qPCR array for genes regulated in apoptotic pathways. In
vitro-differentiated mouse mast cells (BMMC) were kept either under cytokine-omitted or IL-3 (10 ng/ml)-exposed conditions for 2 h. Using the SA Biosciences software, Ct values
were normalized to the average of five different housekeeping genes (β actin, β2 microglobulin, Gapdh, Gusb and Hsp90ab1) and linearized with the standard formula for qPCR
(2− (Ctsample–Ctcontrol)). While y axis displays the expression of IL-3 treated cells, the x axis shows its corresponding level of untreated cells. Continuous line matches the
expression upon IL-3 with the expression of untreated, while dotted lines display a threshold of twofold increase/decrease of the mRNA expression comparing IL-3 over untreated.
See complete gene list in Supplementary Table S1. (b) Quantitative RT-PCR (qPCR) analysis of Bcl-2, Bcl-xL, Mcl-1, Bim and Puma expression upon IL-3-treated relative to
cytokine-withdrawn BMMC; n= 3, means±S.D. Statistical analysis was performed by unpaired t-test with post hoc Holm–Sidak multiple comparison correction, P-values
indicated within the graph. (c) Representative quantitative western blots using near-infrared fluorescence of in vitro-differentiated mouse mast cells (BMMC) treated with various
BH3 mimetics at indicated concentrations after IL-3 (10 ng/ml) conditioning or cytokine withdrawal for 4 h (n⩾ 3). (d) Quantitative analysis of western blot data as shown in (c)
displayed as fold change upon IL-3 over untreated, normalized to tubulin expression; n⩾ 3, means± S.D.
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applications for immunological disorders driven by these
cell types.
Materials and Methods
Mice and reagents. C57BL/6 mice were maintained under pathogen-free
conditions in IVC cages. Animal experiments were approved by the animal
experimentation review board of the canton of Bern (BE31/11 and BE12/14).
RPMI-1640 AQmedia, propidium iodide (PI) and Eukitt were purchased from
Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). Fetal calf serum (FCS, Sera Pro,
ultra-low endotoxin) was purchased from Pan Biotech (Aidenbach, Germany).
2-mercaptoethanol (2-ME), 4-hydroxytamoxifen (4-OHT), and penicillin/streptomycin
were from Life Technologies (Carlsbad, CA, USA). WEHI-3B cell-conditioned medium
was used as a source of mouse interleukin-3 and was produced as previously
described.27,50 Recombinant mouse IL-3 was purchased from Peprotech (London,
UK). Q-VD-OPh was purchased from SM Biochemicals (Anaheim, CA, USA).
Recombinant His6-tagged GFP-Annexin V was purified in-house as previously
described.51,52 Pancoll human (density 1.077 g/ml) was purchased from Pan Biotech,
while EasySep Human Basophil Enrichment Kit was bought from StemCell
Technologies (Vancouver, Canada). ABT-199 (Venetoclax) was manufactured by
BioVision (Milpitas, CA, USA), ABT-263 (Navitoclax) and A-1210477 by Selleck
Chemicals (Houston, TX, USA), while WEHI-539 hydrochloride was purchased from
Hycultec (Beutelsbach, Germany).
Generation of bone marrow-derived mouse mast cells. To generate
mast cells, total bone marrow isolated from femurs and pelvises were taken into
culture in RPMI-1640 AQmedia (Sigma-Aldrich Chemie GmbH) supplemented with
10% FCS, 1% penicillin/streptomycin, 50 μM 2-mercaptoethanol (2-ME) and 10% of
WEHI-3B cell-conditioned medium as a source of IL-3 (200 pg/ml final
concentration) (protocol adapted from Swindle53). After 4 weeks, mast cells were
checked for their maturity measuring CD117 (c-kit) and FcεRI surface expression
by flow cytometric analysis. In general, the purity of CD117+FcεRI+ mast cells within
the BMMC culture was between 95 and 99% (Supplementary Figure S4).
In vitro differentiation of mouse basophils. Conditional Hoxb8
immortalized basophil committed myeloid progenitors, termed IL-3condHoxb8 cells,
were generated from bone marrow of WT mice as previously described.27,28 Cells
were cultured in RPMI-1640 AQmedia supplemented with 10% FCS, 100 U/ml
penicillin/streptomycin, 10% WEHI-3B cell-conditioned medium as a source of IL-3
(200 pg/ml final concentration, as determined by ELISA) and 0.1 μM 4-OHT. Upon
removal of 4-OHT fully mature basophils were generated within 6 days. To confirm
the complete differentiation into mature basophils, cells were stained for the surface
marker profile CD117/c-kit-FcεRI+, using the following antibodies (all from
BioLegend, San Diego, CA, USA): hamster anti-FcεRI (clone MAR-1) and rat
anti-CD117 (c-kit, clone 2B8), and measured by flow cytometry (FACS Verse, BD
BioSciences, Allschwil, CH) (see Gurzeler et al.27 and Reinhart et al.28). Data were
analyzed by FlowJo V.10.1 (Ashland, OR, USA).
Human basophil isolation from human peripheral blood. This
study was approved by the local ethical committee (108/14). Upon informed consent
of healthy donors, peripheral blood was collected into sterile lithium heparin BD
Vacutainer (BD BioScience) and diluted 1:1 in PBS. This diluted blood was then
carefully layered on top of Pancoll human (density 1.077 g/ml) and centrifuged at
800 × g for 20 min. The serum on top of the intermediate phase was aspirated, while
the whitish peripheral mononuclear cell (PBMC) population was collected. After two
washing steps, basophils were negatively sorted from PBMC fraction using
EasySep Human Basophil Enrichment Kit from StemCell Technologies. Following
the manufacturer’s protocol, 0.75–3 × 106 basophils could be isolated per 100 ml of
blood, depending on the donor.
Morphology of both human and mouse basophils and mast cells was analyzed by
microscopy (AxioObserver.Z1 fluorescence/light microscope; Zeiss, Oberkochen,
Germany) of DiffQuik (Baxter, Deerfield, IL, USA)-stained cytospins (data not shown).
Cell death measurement by flow cytometric analysis. After
differentiation of basophils and BMMC, cells were thoroughly washed with PBS
prior to incubation with the indicated stimuli, in the presence or absence of high
concentrations (10 ng/ml) of recombinant mouse IL-3. Basophils were stained
with GFP-Annexin V diluted in FACS buffer (150 mM NaCl, 4 mM KCl, 2.5 mM
CaCl2, 1 mM MgSO4, 15 mM HEPES pH 7.2, 2% FCS and 10 mM NaN3) for
20 min on ice in the dark. Following one washing step with FACS buffer, cells were
resuspended in FACS buffer containing 2 μg/ml of PI and subsequently measured
by flow cytometry (FACS Verse, BD BioScience). Data were analyzed using
FlowJo version 10.1., where GFP-Annexin V and PI double-negative cells were
considered as viable cells and displayed as percentage of overall survival at
indicated time points.
Gel electrophoresis and quantitative immunoblotting. After wash-
ing with PBS, ca. 3 × 106 cells were directly lysed in pre-heated H8-Buffer (20 mM
Tris/HCl pH 7.5, 2 mM EGTA, 2 mM EDTA, 1% SDS, supplemented with 50–
100 mM DTT) and boiled at 95 °C for 10 min. The lysates were subsequently
homogenized and boiled again for 5 min after addition of 4 × Lämmli buffer
(supplemented with 100 mM DTT). Proteins were separated on 12.5 or 15%
denaturing SDS-PAGE gels and transferred to PVDF membrane (Immobilon-FL,
0.45 μM, Merck Millipore, Zug, Switzerland). After blocking, the membranes
were probed overnight with the following primary antibodies: mouse anti-BCL-2
(clone 10C4, BioLegend); rat anti-BIM (clone 3C5) and rat anti-MCL-1 (clone 19C4);
kind gifts from D Huang (Parkville, Victoria, Australia), rabbit polyclonal anti-BCL-XL
from Santa Cruz (S-18, Dallas, TX, USA); rabbit polyclonal anti-pro-caspase-3
(#9662), anti-cleaved-caspase-3 (#9661) and polyclonal anti-PUMA (#7467) from
Cell Signaling (Danvers, MA, USA); mouse anti-tubulin (clone B-5-1-2) from Sigma
Aldrich (St. Louis, MO, USA). For all immunoblots with total lysates, infrared dye-
conjugated secondary antibodies (LI-COR Biosciences, Bad Homburg, Germany)
were used. All immunoblots were analyzed with the Odyssey Fc Dual-Mode Imaging
System using the ImageStudio software 3.1.4 (LI-COR).
Detection of active caspase-3 and -7. Basophils or mast cells
of 2–4 × 105 were treated with specified concentrations of BH3 mimetics for
indicated time points. Active caspase-3 and -7 were stained using CellEvent
Caspase-3/7 Green Detection Reagent (Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Signals were acquired with a Zeiss
AxioObserver.Z1 fluorescence microscope using the Zen Blue software (ZEN pro
2012, Zeiss). In addition, cells positive for active caspase-3 and -7 were counted by
flow cytometry using the FACS Verse (BD BioScience) and analyzed by FlowJo
version 10.1.
Quantitative PCR and RT2 profiler PCR array. Basophils or mast cells
of 3–5 × 106 were incubated for indicated time and compound concentrations,
collected, washed twice in PBS and snap-frozen until further procession. mRNA
was than isolated using SV Total RNA Isolation System from Promega (Madison,
WI, USA). Using all chemicals for the subsequent cDNA production also from
Promega, we proceeded by a denaturation and primer annealing step, incubating
1 μg total RNA (measured by NanoDrop) per reaction with 0.5 μg oligo d(T) at 70 °
C for 5 min with shock cool on ice. The reverse transcription reaction was than
performed by adding 5 × M-MLV reaction buffer, 10 mM dNTP, 25.2 U RNAse
inhibitor, 200 U m-MLV RTand nuclease-free water to the before-prepared RNA mix
and was incubated for 1 h at 42 °C before inactivating the reverse transcriptase at
70 °C for 10 min. The following qPCR was completed by 5 × HOT FIREPol
EvaGreen qPCR Mix Plus (Solis BioDyne, Tartu, Estonia) using Hprt as reference
Figure 6 Viability of mouse mast cells prominently depends on BCL-2 and MCL-1. (a) Enzymatic caspase-3 activity assay (CellEvent) displayed with images of fluorescence
microscopy showing active caspase-3 in green, PI positive cells in orange and double-positive in vitro-differentiated mast cells (BMMC) in yellow after 6 h of treatment with the
different BH3 mimetics at indicated concentrations in the presence or absence of IL-3 (10 ng/ml). Representative pictures are shown (n⩾ 4). (b) Quantitative analysis of active
caspase-3 and PI staining measured by flow cytometric analysis of same samples shown in (a); n= 4, means± S.D. For statistical analysis, see Supplementary Table S4.
(c) Survival of BMMC over time defined as GFP-Annexin V/PI double-negative staining and quantified by flow cytometry after BH3 mimetic treatment at indicated concentrations
with or without IL-3 (10 ng/ml); n⩾ 4 means± S.D.
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gene for normalization. qPCR was run with Bio-Rad CFX Connect Real-Time
System (Hercules, CA, USA). Primers were designed as follows: mmBcl-2 fw 5′-
tgaagcggtccggtggatac-3′, rev 5′-ggcggcggcagatgaattac-3′; mmBcl-xL fw 5′-cactgtgc
gtggaaagcgta-3′, rev 5′-ctcggctgctgcattgttcc-3′; mmMcl-1 fw 5′-ggacgacctataccg
ccagt-3′, rev 5′-cggagcatgccctggaag-3′; mmBim fw 5′-gagttgtgacaagtcaac
acaaacc-3′, rev 5′-gaagataaagcgtaacagttgtaagataacc-3′; mmPuma fw 5′-atgcctgcctc
accttcatct-3′, rev 5′-agcacaggattcacagtctgga-3′.
PCR array was purchased from QIAGEN (Venlo, Netherlands). RNA and cDNA
were generated as described above and using the same FIREPol EvaGreen qPCR
master mix, array was run in CFX Connect cycler with the following program: 15 min
at 95 °C, starting 40 cycles with 15 s at 95 °C, 1 min at 60 °C followed by 1 min at
72 °C before reading. Data analysis was performed using the supplier's (SA
Biosciences, Frederick, MD, USA) PCR array data analysis software and displayed in
Prism 6 generated graph.
Statistical analysis. Data from qPCR were statistically analyzed by unpaired
t-test with post hoc Holm–Sidak for multiple comparison correction, α= 5%. Viability
assays over time were statistically analyzed by two-way ANOVA followed by Sidak
multiple comparison correction. Significant differences in different population from
the CellEvent analysis were analyzed by two-way ANOVA with post hoc test of
Turkey’s multiple comparison correction, P-values are shown in Supplementary
Tables S2–S4. All values are represented as means± S.D. All statistical analyses
were performed using Prism 6 software (GraphPad, La Jolla, CA, USA).
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